Jevtana

Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid.[2] It is a microtubule inhibitor,[1] and the fourth taxane to be approved as a cancer therapy.[citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010.[3][4][5] It... [wikipedia]